Implants lower IOP, reduce medication

The findings have potential clinical and public health implications and highlight the greater role of metabolic health status than obesity in IOP elevation, according to the authors.

The procedure can provide prolonged IOP lowering in primary open-angle glaucoma with an excellent safety profile.

Automated AI tool offers offline capability and hope for patients.

Examining the anatomy and physiology may prevent ineffective stent implantation.

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.

Ruth Williams, MD, explained the importance of hypotension in glaucoma and its potential as a modifiable risk factor at the 27th annual Glaucoma Symposium during Glaucoma 360 at the Westin St. Francis San Francisco on Union Square.